doc_id,sentence_id,product_a,product_b,section,sentence_text,narrative_type,narrative_subtype,narrative_confidence,narrative_invariant_ok,narrative_invariant_reason
med:pmid:33725113,med:pmid:33725113:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"The use of triple HF therapy (ACEI/ARB/angiotensin receptor neprilysin inhibitor with β-blockers and MRA) was higher in the S/V groups than non-S/V group (48.2%, 48.2%, and 40.2% in rS/V, S/V, and non-S/V, respectively).",,,,,
med:pmid:34969175,med:pmid:34969175:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Compared with enalapril, sacubitril/valsartan reduced the risk of a ventricular arrhythmia (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.62-0.95; p = 0.015) and the composite arrhythmia outcome (HR 0.79, 95% CI 0.65-0.97; p = 0.025).",,,,,
med:pmid:34989105,med:pmid:34989105:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"We assessed the effect of treatment (sacubitril/valsartan vs. enalapril or valsartan) on a composite of either ≥50% reduction in estimated glomerular filtration rate (eGFR), ESRD, or death from renal causes, in addition to changes in eGFR slope.",,,,,
med:pmid:34989105,med:pmid:34989105:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"The composite renal outcome occurred in 70 of 6594 patients (1.1%) in the sacubitril/valsartan group and in 123 of 6601 patients (1.9%) in the valsartan or enalapril group (hazard ratio 0.56, 95% confidence interval [CI] 0.42-0.75; p < 0.001).",,,,,
med:pmid:35022763,med:pmid:35022763:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"Overall, treatment with sacubitril/valsartan or omapatrilat showed a slightly lower risk of any renal event [OR 0.82 (0.7-0.97)] compared with treatment with an ACEi or ARB alone.",,,,,
med:pmid:35081164,med:pmid:35081164:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,Sacubitril/valsartan was similar to either enalapril or valsartan in preventing the occurrence of AF in patients with HF.,,,,,
med:pmid:35115085,med:pmid:35115085:sec:conclusion:sent:12,enalapril,sacubitril_valsartan,conclusion,"Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction [EVALUATE-HF]; NCT02874794) (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183).",,,,,
med:pmid:35282662,med:pmid:35282662:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Secondary outcomes occurred in 13 participants (20.3%) in the ARNI group and 22 participants (34.4%) in the enalapril group [hazard ratio (HR), 0.56; 95% CI: 0.28 to 1.12; P=0.102].",,,,,
med:pmid:35301107,med:pmid:35301107:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"Among eligible patients, 33%, 25% and 55% were not prescribed ACEI/ARB/ARNI, beta-blocker, and MRA at discharge, respectively; 99% were not prescribed SGLT2i.",,,,,
med:pmid:35301107,med:pmid:35301107:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"In-hospital rates of initiation/dose increase were 20% for ACEI/ARB, 4% for ARNI, 20% for beta-blocker, 22% for MRA, and < 1% for SGLT2i; corresponding rates of dose decrease/discontinuation were 11%, 2%, 9%, 5%, and < 1%, respectively.",,,,,
med:pmid:35332595,med:pmid:35332595:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"In a sensitivity analysis considering the ARNI and non-ARNI subgroups of SGLT2i RCTs, the combination SGLT2i + ARNI + BB + MRA was associated with the lowest HR (0.28, 95% CrI 0.16-0.45 vs. 0.40, 95% CrI 0.24-0.60 for SGLT2i + BB + ACEi + MRA).",,,,,
med:pmid:35350535,med:pmid:35350535:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Medical therapy significantly changed over the last decade in terms of higher use of angiotensin receptor blockers (ARBs), lower use of angiotensin-converting enzyme inhibitors (ACEIs), and the introduction of angiotensin receptor-neprilysin inhibitors (ARNIs).",,,,,
med:pmid:35360037,med:pmid:35360037:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"We used inverse probability of treatment weighting (IPTW) to balance baseline covariates, and compared outcomes between ARNI and ACEI/ARB users.",,,,,
med:pmid:35360037,med:pmid:35360037:sec:results:sent:5,enalapril,sacubitril_valsartan,results,There were 206 patients in the ARNI group and 833 patients in the ACEI/ARB group.,,,,,
med:pmid:35360037,med:pmid:35360037:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"After IPTW adjustment, the mean follow-up durations were 7.3 months and 6.6 months in the ARNI and ACEI/ARB groups, respectively.",,,,,
med:pmid:35404555,med:pmid:35404555:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"Of the 29 studies, 11 examined BBs; 9, MRAs; 6, ARNis; 2, ACEis; and 1, ARBs.",,,,,
med:pmid:35483448,med:pmid:35483448:sec:conclusion:sent:12,enalapril,sacubitril_valsartan,conclusion,The ARNI study group showed better safety and efficacy outcomes at the end of 6 months follow-up compared to ACEI group.,,,,,
med:pmid:35483448,med:pmid:35483448:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"A total of 200 patients were included in the present study, 100 each in ARNI and ACEI group.",,,,,
med:pmid:35483448,med:pmid:35483448:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"The mean age of the population was 61.2 ± 8.4 years and 62.6 ± 8.6 years in ARNI group and ACEI group, respectively.",,,,,
med:pmid:35483448,med:pmid:35483448:sec:results:sent:9,enalapril,sacubitril_valsartan,results,The mean maximum tolerated dose by population in ARNI group was 203.6 mg and 8.9 mg in ACEI group.,,,,,
med:pmid:35525261,med:pmid:35525261:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"We then used risk reductions from the SOLVD, PARADIGM-HF and PIONEER-HF trials to estimate the benefits of ACEi/ARB and sacubitril/valsartan.",,,,,
med:pmid:35525261,med:pmid:35525261:sec:results:sent:8,enalapril,sacubitril_valsartan,results,The benefit of sacubitril/valsartan over ACEi/ARB did not decrease with increasing age - the number needed to treat among 66 to 74-year-old patients was 84 and among 85+ year-old patients was 67.,,,,,
med:pmid:35546745,med:pmid:35546745:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"The patients taking ACE inhibitors and mTOR inhibitors, DPP4 inhibitors, alteplase, or sacubitril/valsartan concurrently may be at increased risk of developing angioedema.",,,,,
med:pmid:35851740,med:pmid:35851740:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"The proportions receiving a prescription for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ACEi/ARB/ARNi) were 96%, 92%, 86%, and 68%, for estimated glomerular filtration rate (eGFR) ≥60, 45-59, 30-44, and <30 ml/min/1.73 m<sup>2</sup> , respectively; for beta-blockers 94%, 93%, 92%, and 92%, for mineralocorticoid receptor antagonists (MRAs) 45%, 44%, 37%, 24%; and for triple therapy (combination of ACEi/ARB/ARNi + beta-blockers + MRA) 38%, 35%, 28%, and 15%.",,,,,
med:pmid:35851740,med:pmid:35851740:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"Patients with CKD were less likely to initiate these medications, and less likely to adhere to and persist on ACEi/ARB/ARNi, MRA, and triple therapy.",,,,,
med:pmid:35902033,med:pmid:35902033:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,"In this population-based study, most patients with newly diagnosed HFrEF received beta-blockers and ACEis/ARBs/ARNIs.",,,,,
med:pmid:35902033,med:pmid:35902033:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"In models accounting for the role of an HF clinic in initiation of these medications, being seen in an HF clinic was independently associated with initiation of new GDMT across all medication classes, with a hazard ratio (95% CI) of 1.54 (1.15-2.06) for any beta-blocker, 2.49 (1.95-3.20) for HF beta-blockers, 1.97 (1.46-2.65) for ACEis/ARBs/ARNIs, and 2.14 (1.49-3.08) for MRAs.",,,,,
med:pmid:35902033,med:pmid:35902033:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"We examined the use of beta-blockers, HF beta-blockers (metoprolol succinate, carvedilol, bisoprolol), angiotensin converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), angiotensin receptor neprilysin inhibitors (ARNIS), and mineralocorticoid receptor antagonists (MRAs) in the first year after HFrEF diagnosis.",,,,,
med:pmid:35902033,med:pmid:35902033:sec:results:sent:8,enalapril,sacubitril_valsartan,results,Most eligible patients received beta-blockers (92.6%) and ACEis/ARBs/ARNIs (87.0%) in the first year.,,,,,
med:pmid:35990952,med:pmid:35990952:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,"Compared with ACEI/ARB, sacubitril/valsartan was more effective.",,,,,
med:pmid:35990986,med:pmid:35990986:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"Among 679 eligible patients, 155 patients with ARNI treatment and 155 patients with ACEI treatment were included in the analyses.",,,,,
med:pmid:35990986,med:pmid:35990986:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"At a median follow-up of 228 (196-322) days, ARNI as compared with ACEI was associated with a lower risk of AF recurrence [adjusted hazard ratio (HR), 0.39; 95% confidence interval (CI), 0.24-0.63; <i>p</i> < 0.001].",,,,,
med:pmid:35999128,med:pmid:35999128:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"Of the 1,698 patients identified, ACEi/ARB/ARNI, beta blockers and MRA were dispensed in 80.2%, 83.6% and 45.4%, respectively, prior to ICD implant.",,,,,
med:pmid:36051320,med:pmid:36051320:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Prescription of evidence-based treatment at baseline included sacubitril/valsartan (10%), ACEI (33%), ARB (41%), beta-blocker (79%), diuretics (68%), and MRA (56%).",,,,,
med:pmid:36128010,med:pmid:36128010:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,"There was no significant difference between the doses of BB, ACEI, ARB, MRA, or ARNI among HFrEF patients on digoxin compared to those that were not.",,,,,
med:pmid:36128010,med:pmid:36128010:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"There was no significant difference between the two groups in terms of patients receiving higher doses of BB (P = 0.235), ACEI/ARB (P = 0.903), MRA (P = 0.331), or ARNI (P = 0.717).",,,,,
med:pmid:36132549,med:pmid:36132549:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"However, HFpEF patients that underwent ARNI treatment achieved better outcomes than did patients that underwent ACEI treatment.",,,,,
med:pmid:36202739,med:pmid:36202739:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"Pooled across countries, proportions of patients who discontinued therapy (not including switches from ACE inhibitor or ARB to sacubitril/valsartan) within 12 months were 23.5% (dapagliflozin), 26.4% (sacubitril/valsartan), 38.4% (ACE inhibitors), 33.4% (ARBs), 25.2% (beta-blockers), and 42.2% (MRAs).",,,,,
med:pmid:36252108,med:pmid:36252108:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Achievement of ≥50% target dose was low (beta blocker 45.9%, ACE inhibitor/angiotensin receptor blocker 31.6%, ARNI 19.0%) and for ACE inhibitor/angiotensin receptor blocker/ARNI, decreased over time.",,,,,
med:pmid:36266969,med:pmid:36266969:sec:results:sent:13,enalapril,sacubitril_valsartan,results,"Within the RASi group, persistence was higher for ARNI than for ACEI and ARB.",,,,,
med:pmid:36304540,med:pmid:36304540:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"In terms of the incidence of adverse reactions, the incidence of cough in ARNI was lower than that in ACEI/ARB group [RR = 0.69, 95%CI(0.60, 0.80), <i>P</i> < 0.00001], but the incidence of hypotension was higher [RR = 1.29, 95%CI(1.18, 1.41), <i>P</i> < 0.00001], and the adverse reactions of hyperkalemia, angioedema and renal insufficiency were not increased (<i>P</i> > 0.05).",,,,,
med:pmid:36348348,med:pmid:36348348:sec:conclusion:sent:10,enalapril,sacubitril_valsartan,conclusion,"No treatments were effective in reducing mortality, but ARNIs, ACEIs or SGLT2 inhibitors reduced HF hospitalizations and only SGLT2 inhibitors reduced WHF events for patients with HFpEF.",,,,,
med:pmid:36440034,med:pmid:36440034:sec:results:sent:16,enalapril,sacubitril_valsartan,results,"Among 211 patients who were already in treatment with ACEi/ARB and 36 patients who were sacubitril/valsartan naive, the improvement of cardiac function demonstrated by clinical outcomes and echocardiographic parameters were similar to the previous one of the 247 MHD patients with HFpEF.",,,,,
med:pmid:36443599,med:pmid:36443599:sec:conclusion:sent:8,enalapril,sacubitril_valsartan,conclusion,"In this nationwide real-world study including a population of patients with HF with reduced or mildly reduced EF, ARNI as part of guideline-led Swedish clinical practice was associated with a statistically significant relative risk reduction in all-cause mortality compared with ACEi/ARB.",,,,,
med:pmid:36470212,med:pmid:36470212:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"During hospitalization, the use of RASi (69% vs. 89%) (ACEI/ARBs [58% vs. 70%], ARNI [10% vs. 19%]), βBs (69% vs. 85%), and MRAs (61% vs. 95%) increased significantly (p < 0.05) compared to at admission, and the use of SGLT2i (3% vs. 11%) also rose (p = 0.0005).",,,,,
med:pmid:36475871,med:pmid:36475871:sec:conclusion:sent:10,enalapril,sacubitril_valsartan,conclusion,Sacubitril/valsartan may have the potential to improve HRQoL in heart failure patients with reduced ejection fraction compared with ACEI/ARB.,,,,,
med:pmid:36475871,med:pmid:36475871:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,Hypotension is the most common adverse event with sacubitril/valsartan compared with ACEI/ARB.,,,,,
med:pmid:36475871,med:pmid:36475871:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"A total of 8 studies with 17 390 patients (8693 patients used sacubitril/valsartan, and 8697 patients used ACEI/ARB) were included in this study.",,,,,
med:pmid:36475871,med:pmid:36475871:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"The KCCQ overall summary score and its subscales were significantly higher in sacubitril/valsartan compared with ACEI/ARB in heart failure patients with reduced ejection fraction, but were similar in heart failure patients with preserved ejection fraction.",,,,,
med:pmid:36475871,med:pmid:36475871:sec:results:sent:8,enalapril,sacubitril_valsartan,results,Sacubitril/valsartan conferred similar HRQoL scores in MLHFQ and SF-12/36 to ACEI/ARB.,,,,,
med:pmid:36475871,med:pmid:36475871:sec:results:sent:9,enalapril,sacubitril_valsartan,results,The most frequently reported adverse event for sacubitril/valsartan is hypotension and the risk is higher than for ACEI/ARB.,,,,,
med:pmid:36516938,med:pmid:36516938:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"After propensity score matching, 839 patients were matched in each of the ARNI and ACEI/ARB groups.",,,,,
med:pmid:36527023,med:pmid:36527023:sec:conclusion:sent:17,enalapril,sacubitril_valsartan,conclusion,ACEI/ARB also had a beneficial effect but the effect was weaker than that of sacubitril/valsartan.,,,,,
med:pmid:36527023,med:pmid:36527023:sec:results:sent:14,enalapril,sacubitril_valsartan,results,"Compared with ACEI/ARB, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among patients with HF (RR 1.85, 95% CI 1.12-3.06, p = 0.02) and HFpEF (RR 3.59, 95% CI 1.51-8.55, p = 0.004).",,,,,
med:pmid:36609948,med:pmid:36609948:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"This study enrolled 3735 HFrEF patients with a mean left ventricular EF of 27.56 ± 5.86%, who had been prescribed sacubitril/valsartan (N = 1708) or ACEI/ARB (N = 2027).",,,,,
med:pmid:36609948,med:pmid:36609948:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"After propensity score matching, the clinical and renal outcomes did not differ between the sacubitril/valsartan and ACEI/ARB groups in patients without CKD.",,,,,
med:pmid:36713022,med:pmid:36713022:sec:results:sent:7,enalapril,sacubitril_valsartan,results,All received angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI) at recruitment; 45% received ≥50% maximal targeted dose (MTD) with % MTD of 44.4 ± 31.7%.,,,,,
med:pmid:36713022,med:pmid:36713022:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"At 120 days, 70% received ≥50% MTD ACEI/ARB/ARNI (<i>P</i> = 0.110) with % MTD increased to 64.4 ± 33.5% (<i>P</i> = 0.060).",,,,,
med:pmid:36871177,med:pmid:36871177:sec:results:sent:10,enalapril,sacubitril_valsartan,results,A total of 284 AF events were reported in the sacubitril/valsartan group compared to 256 AF events in ACEIs/ARBs.,,,,,
med:pmid:36871177,med:pmid:36871177:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"Patients on sacubitril/valsartan were as likely as patients on ACEIs/ARBs to develop AF (pooled odds ratio [OR] = 1.091, 95% confidence interval [CI] = 0.917-1.298, p = .324).",,,,,
med:pmid:36871177,med:pmid:36871177:sec:results:sent:12,enalapril,sacubitril_valsartan,results,Six atrial flutter (AFl) events were reported in six trials; 48 out of 9165 patients in the sacubitril/valsartan group developed AFl compared to 46 out of 8759 in ACEi/ARBs group.,,,,,
med:pmid:36871177,med:pmid:36871177:sec:results:sent:14,enalapril,sacubitril_valsartan,results,"Finally, sacubitril/valsartan did not reduce the risk of atrial arrhythmias (AF + AFl) compared to ACEi/ARBs (pooled OR = 1.081, 95% CI = 0.922-1.269, p = .337).",,,,,
med:pmid:36871177,med:pmid:36871177:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"A total of 11 trials including 11,458 patients on sacubitril/valsartan and 10,128 patients on ACEI/ARBs were identified.",,,,,
med:pmid:37115135,med:pmid:37115135:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"Beta-blockers were the most frequently tolerated GDMT (93.1%), followed by ACEIs/ARBs/ARNIs (68.5%), and then MRAs (55.0%).",,,,,
med:pmid:37115135,med:pmid:37115135:sec:results:sent:8,enalapril,sacubitril_valsartan,results,Goal doses were uncommonly achieved for beta-blockers (32.3%) and ACEIs/ARBs/ARNIs (10.2%) due to intolerances limiting titration.,,,,,
med:pmid:37143752,med:pmid:37143752:sec:conclusion:sent:13,enalapril,sacubitril_valsartan,conclusion,Sacubitril/valsartan is associated with better outcomes and may be cost-effective compared to enalapril for the management of HFrEF.,,,,,
med:pmid:37217135,med:pmid:37217135:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"The proportion of patients receiving an angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor blockers (ARB), an angiotensin receptor-neprilysin inhibitor (ARNi), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), or a mineralocorticoid receptor antagonist (MRA) progressively decreased with lower eGFR categories.",,,,,
med:pmid:37217135,med:pmid:37217135:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Notably, 32% of the patients with HFrEF and an eGFR <30 mL/min/1.73 m<sup>2</sup> received the combination of ACEI/ARB/ARNi+beta-blockers+MRA+SGLT2i.",,,,,
med:pmid:37313196,med:pmid:37313196:sec:conclusion:sent:12,enalapril,sacubitril_valsartan,conclusion,"Sacubitril/valsartan had better clinical, intermediate, and renal outcomes in HF in comparison to ACEI or ARB.",,,,,
med:pmid:37374004,med:pmid:37374004:sec:conclusion:sent:12,enalapril,sacubitril_valsartan,conclusion,"In current clinical practice, the majority of patients with reduced and mildly-reduced LVEF are treated by ACEI/ARB and beta-blockers early following ACS, whereas MRA is underutilized and the adoption of SGLT2I and ARNI is low.",,,,,
med:pmid:37429446,med:pmid:37429446:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"Compared to the ACEI/ARB group, the ARNI group had greater relative improvement in LV global longitudinal strain (GLS) (28% versus 11% increase from baseline, p < 0.001) and RV-GLS (11% versus 4% increase from baseline, p < 0.001), and greater relative improvement in New York Heart Association functional class (-14 versus -2% change from baseline, p = 0.006) and N-terminal pro-brain natriuretic peptide levels (-29% versus -13% change from baseline, p < 0.001).",,,,,
med:pmid:37435776,med:pmid:37435776:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"SGLT-2 inhibitors reduced the risk of CV death or hospitalization for HF regardless of background use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), b-blockers, diuretics, mineralocorticoid receptor antagonists (MRAs), or triple combination therapy of either an ACEI/ARB plus b-blocker plus MRA, or an ARNI plus b-blocker plus MRA (HRs ranged from 0.61 to 0.83; P > .1 for each subgroup interaction).",,,,,
med:pmid:37558137,med:pmid:37558137:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"216 DCM patients were enrolled (52 years, 78% male, NYHA I-II 82%, LVEF 32%, 94% on ACE inhibitors/ARNI, 95% on beta-blockers).",,,,,
med:pmid:37646297,med:pmid:37646297:sec:results:sent:2,enalapril,sacubitril_valsartan,results,"In this cross-sectional survey, we investigated the price, affordability, and accessibility of four pivotal classes of HFrEF GDMT: angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or angiotensin-neprilysin inhibitors (ARNI); beta-blockers; mineralocorticoid receptor antagonists (MRA); and sodium glucose co-transporter 2 inhibitors (SGLT2i).",,,,,
med:pmid:37705397,med:pmid:37705397:sec:results:sent:4,enalapril,sacubitril_valsartan,results,The present study enrolled patients with HF with reduced ejection fraction (HFrEF) who were treated with either ARNI or ACEIs/ARBs within 1 year of undergoing index echocardiography.,,,,,
med:pmid:37705397,med:pmid:37705397:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"ARNI had a significantly lower event rate than ACEIs/ARBs in patients with HF with improved ejection fraction (7.0% vs. 30.4%, P = 0.020) and those with persistent HFrEF (17.6% vs. 49.7%, P < 0.001).",,,,,
med:pmid:37705397,med:pmid:37705397:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Irrespective of whether patients exhibited LV reverse remodelling (15.8% vs. 31.1%, P = 0.001) or not (15.0% vs. 54.9%, P < 0.001), ARNIs were associated with a significantly lower event rate than ACEIs/ARBs.",,,,,
med:pmid:37759279,med:pmid:37759279:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"We reviewed 464 articles, including 144 articles that had information about beta-blockers (BB), 179 articles about angiotensin-converting enzyme inhibitors (ACEi), 75 articles about angiotensin receptor blockers (ARB), 80 articles about diuretics, 37 articles about mineralocorticoid receptor antagonists (MRA), and 33 articles about angiotensin receptor-neprilysin inhibitor (ARNI).",,,,,
med:pmid:37933184,med:pmid:37933184:sec:results:sent:3,enalapril,sacubitril_valsartan,results,Patients (n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA.,,,,,
med:pmid:37933210,med:pmid:37933210:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"Beta-blockers (BB) were administered to 574 (82%) patients, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or angiotensin receptor-neprilysin inhibitors (ACEi/ARB/ARNI) were administered to 381 (55%) patients and 416 (60%) received mineralocorticoid receptor antagonists (MRA).",,,,,
med:pmid:37933210,med:pmid:37933210:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"Overall, ≥50% of target doses were reached in 41%, 22%, and 56% of the patients on BB, ACEi/ARB/ARNI and MRA, respectively.",,,,,
med:pmid:37933210,med:pmid:37933210:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"Hypotension, bradycardia, kidney dysfunction and hyperkalaemia were the main causes of underprescription and/or underdosing, but up to a half of the patients did not receive target doses for unknown causes (51%, 41%, and 55% for BB, ACEi/ARB/ARNI and MRA, respectively).",,,,,
med:pmid:37933210,med:pmid:37933210:sec:results:sent:7,enalapril,sacubitril_valsartan,results,The proportions of patients receiving BB and ACEi/ARB/ARNI were lower among those fulfilling the 2018 HFA-ESC criteria for advanced HF.,,,,,
med:pmid:37940331,med:pmid:37940331:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,"This study suggested that SGLT2i, ARNI and IVA in addition to ACEI+BB+MRA may be better in prolonging time to develop PCO in HFrEF patients.",,,,,
med:pmid:37940331,med:pmid:37940331:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"Our findings suggested that ACEI+BB+MRA+SGLT2i, BB+MRA+ARNI, and ACEI+BB+MRA+IVA had lower probability of PCOs than the conventional triple therapy (ACEI+BB+MRA).",,,,,
med:pmid:37989299,med:pmid:37989299:sec:conclusion:sent:8,enalapril,sacubitril_valsartan,conclusion,The efficacy of sacubitril/valsartan compared with enalapril was consistent across baseline SBP tertiles in Japanese patients from the PARALLEL-HF study.,,,,,
med:pmid:37989299,med:pmid:37989299:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"The incidence of hypotension-related events and reduction or discontinuation of treatment due to hypotension-related events was higher in the lower SBP subgroup, and these events were more frequent in the sacubitril/valsartan than enalapril group.",,,,,
med:pmid:38032698,med:pmid:38032698:sec:conclusion:sent:12,enalapril,sacubitril_valsartan,conclusion,"Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two-thirds do not receive SGLT2i.",,,,,
med:pmid:38032698,med:pmid:38032698:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"The percentage of use of the four pharmacological pillars at the time of recruitment was 70.7% for beta-blockers (BB), 77.4% for angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB II)/angiotensin receptor-neprilysin inhibitor (ARNI), 56.8% for mineralocorticoid receptor antagonists (MRA), and 30.7% for sodium-glucose cotransporter type-2 inhibitors (SGLT2i).",,,,,
med:pmid:38330576,med:pmid:38330576:sec:conclusion:sent:18,enalapril,sacubitril_valsartan,conclusion,The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction.,,,,,
med:pmid:38508844,med:pmid:38508844:sec:introduction:sent:2,enalapril,sacubitril_valsartan,results,Data from randomized trials of sacubitril/valsartan in HF patients with EF ≤40% (PIONEER-HF [Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode] trial) and >40% (PARAGLIDE-HF [Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF] trial) following recent worsening heart failure (WHF) were pooled to examine treatment effect across the EF spectrum.,,,,,
med:pmid:38513366,med:pmid:38513366:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"The prognostic value of treatment with beta-blockers (BB), angiotensin-converting enzyme inhibitors, receptor blockers, or receptor-neprilysin inhibitor (ACEi/ARB/ARNI), mineralocorticoid receptor antagonists (MRA), and sodium-glucose-linked transport protein 2 inhibitors (SGLT2i) was investigated for all-cause mortality at 30 months (a median follow-up) and HF-related rehospitalization.",,,,,
med:pmid:38555468,med:pmid:38555468:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"LASSO regression identified five important predictors: age, Killip classification, B-type natriuretic peptide precursor (NTpro-BNP), left ventricular ejection fraction (LVEF), and the usage of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ACEI/ARB/ARNI).",,,,,
med:pmid:38639469,med:pmid:38639469:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"In the nationwide panel, the proportion of patients with versus without WHFE receiving ≥50% of guideline-recommended dose on index visit was 35% versus 40% for beta blocker, 74% versus 83% for ACEI/ARB/ARNI, and 48% versus 49% for MRA.",,,,,
med:pmid:38639469,med:pmid:38639469:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"The proportion of patients receiving ≥50% of guideline-recommended dose was lower in the GHS: 29% versus 34% for beta-blocker, 16% versus 31% for ACEI/ARB/ARNI, and 18% versus 22% for MRA.",,,,,
med:pmid:38783593,med:pmid:38783593:sec:results:sent:12,enalapril,sacubitril_valsartan,results,"In the overall population, ACEi/ARB/ARNi use was less frequent in case of saltSub recommendations (74% vs. 82%, P = 0.012).",,,,,
med:pmid:38783593,med:pmid:38783593:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"collection included baseline characteristics, the use and recommendations of saltSubs, and the use of GDMTs, which included (i) angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitors (ARNis), (ii) mineralocorticoid receptor antagonists (MRAs), and/or (iii) beta-blockers (BBs).",,,,,
med:pmid:38811344,med:pmid:38811344:sec:conclusion:sent:14,enalapril,sacubitril_valsartan,conclusion,Adding SGLT-2i to ARNI/ACEI + BB + MRA is beneficial for reversing cardiac remodeling.,,,,,
med:pmid:38842957,med:pmid:38842957:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,"These data support continuation of sacubitril/valsartan for heart failure treatment even when eGFR declines below this threshold (PARADIGM-HF [Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure], NCT01035255; and PARAGON-HF [Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction], NCT01920711).",,,,,
med:pmid:38904251,med:pmid:38904251:sec:results:sent:3,enalapril,sacubitril_valsartan,results,"Baseline circulating protein concentrations significantly associated with the primary end point and the timing and occurrence of total heart failure hospitalization and cardiovascular death were identified by recurrent events regression, accounting for multiple testing, adjusted for age, sex, treatment, and anticoagulant use, and compared with published analyses in 2515 patients with heart failure with reduced ejection fraction from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and ATMOSPHERE (Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-Mortality in Patients With Chronic Heart Failure) clinical trials.",,,,,
med:pmid:38938237,med:pmid:38938237:sec:conclusion:sent:10,enalapril,sacubitril_valsartan,conclusion,Sacubitril/valsartan was associated with lower 3-year rates of neurocognitive disorders when compared to ACEI/ARBs in patients with HFrEF.,,,,,
med:pmid:39105079,med:pmid:39105079:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"Out of 349 patients screened, 89 were included in the final analysis (42 in the ARNI group and 47 in the ACEI/ARB group).",,,,,
med:pmid:39105079,med:pmid:39105079:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"The primary composite rate of HHF or mortality was 20.6 events per 100 patient-years in the ARNI group and 26.1 in the ACEI/ARB group; the adjusted hazard ratio was 0.98 (95% CI: 0.28-3.43, <i>P</i> = 0.97).",,,,,
med:pmid:39106509,med:pmid:39106509:sec:discussion:sent:9,enalapril,sacubitril_valsartan,discussion,"of prescribed pathogenetic therapy showed that in patients with HFrEF, the frequency of prescription of ACE inhibitors, â-blockers and MRA decreased (<i>p</i>=0.023, 006 and 0.01, respectively), and ARNI, on the contrary, increased with a decrease in GFR (<i>p</i>=0.026).",,,,,
med:pmid:39156077,med:pmid:39156077:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"The optimal independent predictors for all-cause mortality (<i>APSELNH: A: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI), P: percutaneous coronary intervention/coronary artery bypass graft (PCI/CABG), S: stroke, E: eGFR, L: lg of NT-proBNP</i>, <i>N: NYHA, H: healthcare</i>) were incorporated into the dynamic nomogram.",,,,,
med:pmid:39264627,med:pmid:39264627:sec:conclusion:sent:14,enalapril,sacubitril_valsartan,conclusion,"In this cohort study, sacubitril/valsartan treatment was associated with a potential kidney function benefit in patients with mHTN-associated TMA compared with ACEI/ARB treatment.",,,,,
med:pmid:39264627,med:pmid:39264627:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Among the 217 patients (mean [SD] age, 35.9 [8.8] years; 188 men [86.6%]) included in the study, 66 (30.4%) received sacubitril/valsartan and 151 (69.6%) received ACEI/ARBs at baseline.",,,,,
med:pmid:39264627,med:pmid:39264627:sec:results:sent:6,enalapril,sacubitril_valsartan,results,<h4>Exposures</h4> Treatment with sacubitril/valsartan or ACEI/ARBs during hospitalization and after discharge.,,,,,
med:pmid:39264627,med:pmid:39264627:sec:results:sent:9,enalapril,sacubitril_valsartan,results,Propensity score matching (PSM) and Cox proportional hazards regression analysis were used to evaluate the association between sacubitril/valsartan and ACEI/ARB therapy with kidney recovery outcomes.,,,,,
med:pmid:39284545,med:pmid:39284545:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"However, reduction in mean systolic blood pressure from baseline to study end did not significantly differ (sacubitril/valsartan: -2.2 mmHg vs enalapril: -1.3 mmHg; p = 0.6895).",,,,,
med:pmid:39284545,med:pmid:39284545:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"Hypotension-related AEs leading to treatment discontinuation were not significantly different for sacubitril/valsartan versus enalapril (3.4 % vs 6.9 %, p = 0.5957).",,,,,
med:pmid:39318024,med:pmid:39318024:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"The first drug class initiated in HFrEF was angiotensin-converting enzyme inhibitors/angiotensin receptor-neprilysin inhibitor (ACEi/ARNi) (91.2%), beta-blockers (BB) (73.8%), mineralocorticoid receptor antagonists (MRAs) (53.4%), and sodium-glucose cotransporter 2 (SGLT2) inhibitors (48.1%).",,,,,
med:pmid:39318024,med:pmid:39318024:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"The combination ACEi/ARNi + MRA+ BB was preferred by 39.3% of physicians, ACEi/ARNi + SGLT2 inhibitors + BB by 33.3%, and ACEi/ARNi + BB by 22.2%.",,,,,
med:pmid:39319469,med:pmid:39319469:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,"In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point.",,,,,
med:pmid:39319469,med:pmid:39319469:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children.",,,,,
med:pmid:39320292,med:pmid:39320292:sec:conclusion:sent:12,enalapril,sacubitril_valsartan,conclusion,"Although both asymptomatic and symptomatic hypotension during treatment with sacubitril/valsartan or enalapril were associated with worse outcomes, the benefits of sacubitril/valsartan were maintained (or even enhanced) in patients experiencing hypotension.",,,,,
med:pmid:39320292,med:pmid:39320292:sec:results:sent:10,enalapril,sacubitril_valsartan,results,The safety of sacubitril/valsartan vs enalapril was also maintained regardless of the occurrence of hypotension.,,,,,
med:pmid:39327768,med:pmid:39327768:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"At discharge, the proportions of patients on beta-blockers, angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs)/angiotensin receptor/neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs) were 78% (n = 144), 58% (n = 107) and 55% (n = 101), respectively.",,,,,
med:pmid:39387766,med:pmid:39387766:sec:conclusion:sent:13,enalapril,sacubitril_valsartan,conclusion,Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255; Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).,,,,,
med:pmid:39404722,med:pmid:39404722:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"The present study demonstrates that the addition of dapagliflozin is beneficial in terms of clinical and cost-effectiveness, regardless of the initial regimen (angiotensin receptor-neprilysin inhibitors [ARNI] or angiotensin-converting enzyme inhibitors [ACEi]/angiotensin II receptor blockers [ARB]) of standard drug therapy for HFrEF and in all cases leads to an increase in life expectancy, a decrease in the number of hospitalizations and emergency visits due to CHF, as well as cardiovascular mortality.",,,,,
med:pmid:39404722,med:pmid:39404722:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"In the case of adding dapagliflozin the values of the additional cost of an added year of life in the 3 considered standard therapy options (ARNI or ACEi/ARB, only ACEi/ARB and only ARNI) were 291,256, 279,571 and 338,374 rubles respectively.",,,,,
med:pmid:39455534,med:pmid:39455534:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group.",,,,,
med:pmid:39497472,med:pmid:39497472:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Of 33 patients included in this study, 67% received the full 36-hour washout period when transitioning from ACEi to ARNI.",,,,,
med:pmid:39563094,med:pmid:39563094:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,"Sacubitril/valsartan may be more effective than enalapril in reducing the risk of death in patients not treated with a beta-blocker compared to those treated with a beta-blocker, but is effective regardless of beta-blocker use.",,,,,
med:pmid:39563094,med:pmid:39563094:sec:results:sent:10,enalapril,sacubitril_valsartan,results,Safety outcomes related to sacubitril/valsartan versus enalapril did not differ according to background beta-blocker use.,,,,,
med:pmid:39563094,med:pmid:39563094:sec:results:sent:3,enalapril,sacubitril_valsartan,results,We examined the effect of sacubitril/valsartan compared to enalapril on outcomes according to background beta-blocker treatment in the 8399 patients with heart failure with reduced ejection fraction enrolled in PARADIGM-HF.,,,,,
med:pmid:39571389,med:pmid:39571389:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Key predictors included the E/e' ratio, NYHA classification, LVEF, age, BNP levels, MLR, history of atrial fibrillation (AF), use of ACEI/ARB/ARNI, and history of myocardial infarction (MI).",,,,,
med:pmid:39602121,med:pmid:39602121:sec:results:sent:13,enalapril,sacubitril_valsartan,results,"Not filling a cardiovascular medication after hospitalization was associated with not filling that medication at the time of discharge (adjusted risk ratio, 0.27 [95% CI, 0.27-0.28] for ACEIs, ARBs, or ARNIs; 0.24 [0.24-0.25] for β-blockers; 0.20 [0.19-0.20] for P2Y12Is; 0.31 [0.31-0.32] for statins or PCSK9Is; and 0.27 [0.26-0.28] for SGLT2Is or GLP-1RAs).",,,,,
med:pmid:39602121,med:pmid:39602121:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"<h4>Main outcome and measures</h4> Medicare Part D prescription fill records were examined for the following agents: (1) angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); (2) β-blockers; (3) platelet adenosine diphosphate receptor inhibitors (P2Y12Is); (4) statins or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is); and (5) glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium glucose cotransporter 2 inhibitors (SGLT2Is).",,,,,
med:pmid:39620289,med:pmid:39620289:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Although 69.5% of the study participants indicated prescribing all four classes of HF medications during the initial hospitalization is feasible, most cardiologists preferred a sequential approach starting with ACEi/ARNi, followed by beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).",,,,,
med:pmid:39687932,med:pmid:39687932:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"The proportion of patients who halted GDMT was 70.4%, 53.2%, 59.8% and 63.8% for MRA, beta-blockers, ACEI/ARB/ARNI and SGLT-2 inhibitors.",,,,,
med:pmid:39719408,med:pmid:39719408:sec:results:sent:4,enalapril,sacubitril_valsartan,results,Individual patient data from the PARAGON-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blocker] Global Outcomes in HFpEF) and PARADIGM-HF (Prospective Comparison of ARNI With ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in HF) trials were used to examine patient characteristics and outcomes according to quartiles of PNI.,,,,,
med:pmid:39792134,med:pmid:39792134:sec:results:sent:2,enalapril,sacubitril_valsartan,results,"This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status.",,,,,
med:pmid:39829077,med:pmid:39829077:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Among the 93.8% on some form of GDMT, 82.8%, 81.4%, 23.5%, 3.6% and 13.4% were on ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators (Black patients only), respectively.",,,,,
med:pmid:39829077,med:pmid:39829077:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"Among treated patients, 45.8%, 21.4%, 77.6%, 100% and 14.7% were treated at ≥80% of the target dose for ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators, respectively.",,,,,
med:pmid:39922597,med:pmid:39922597:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,"In our study, early adoption of guideline-recommended medical therapy is still limited, with a significant rise in SGLT2i prescriptions after January 2022 and a lower risk of the composite of all-cause death and urgent readmissions at 30 days restricted to the use of ACEi/ARB/ARNi.",,,,,
med:pmid:39922597,med:pmid:39922597:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"In multivariate analysis, the use of ACEi/ARB/ARNi was associated with a lower risk of 30-day all-cause death and urgent rehospitalisation (adjusted OR 0.38; 95% CI 0.24 to 0.59; p<0.01).",,,,,
med:pmid:39939202,med:pmid:39939202:sec:results:sent:12,enalapril,sacubitril_valsartan,results,Better renal function was a predictor for ACEIs/ARBs/ARNIs at any dose and ≥50% target dose.,,,,,
med:pmid:39983618,med:pmid:39983618:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,Treatment with sacubitril/valsartan or enalapril prevented deterioration of myocardial function at 6 months in patients with hematologic malignancies treated with BMT.,,,,,
med:pmid:40063170,med:pmid:40063170:sec:results:sent:15,enalapril,sacubitril_valsartan,results,"The prescription rates for key medications were as follows: β-blockers 76.4%, ACE inhibitors/ARBs 71.6%, MRA 63.3%, SGLT2I 33.5%, and ARNI 0%.",,,,,
med:pmid:40063170,med:pmid:40063170:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"Medications were classified according to the four-pillar therapy recommended by the AHA, including β-blockers, ARNI, ACE inhibitors/ARBs, SGLT2, and MRAs.",,,,,
med:pmid:40091512,med:pmid:40091512:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"The GDMT score (0-8) factored in doses of beta-blocker (BB), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB), mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), angiotensin receptor-neprilysin inhibitor (ARNI), isosorbide dinitrate/hydralazine (ISDN/HYD).",,,,,
med:pmid:40101251,med:pmid:40101251:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Of these, 95% reached titration to either guideline-recommended target doses or maximum tolerated doses for both angiotensin-converting enzyme inhibitor/angiotensin receptor blockers/angiotensin and angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and beta-blockers combined.",,,,,
med:pmid:40101251,med:pmid:40101251:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"The mean number of days to achieve titration ranged from 20.2 days for mineralocorticoid receptor antagonist drugs, between 27.5 to 32.3 days for ACEI/ARB/ARNI drugs and 41.0 days for beta-blockers; 70 (79%) patients completed the satisfaction survey at least once, with more than 98% of survey questions receiving a positive response.",,,,,
med:pmid:40188960,med:pmid:40188960:sec:conclusion:sent:9,enalapril,sacubitril_valsartan,conclusion,"ACEI/ARB, sacubitril/valsartan, and trimetazidine might improve CMD in patients with DbCM.",,,,,
med:pmid:40188960,med:pmid:40188960:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"Patients with elevated NT-pro-BNP had high AMR, and those grouped by medication indicated that ACEI/ARB, sacubitril/valsartan, and trimetazidine might lower AMR in patients with elevated NT-pro-BNP.",,,,,
med:pmid:40232857,med:pmid:40232857:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"Early quadruple therapy was defined as the prescription of beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) within 48 h of admission.",,,,,
med:pmid:40255655,med:pmid:40255655:sec:results:sent:12,enalapril,sacubitril_valsartan,results,"Key predictors of one-year mortality risk included Beta blockers, ACEI/ARB/ARNI, BNP, CRP, NLR, AF, MI, NYHA class, and age.",,,,,
med:pmid:40255655,med:pmid:40255655:sec:results:sent:13,enalapril,sacubitril_valsartan,results,"SHAP analysis revealed that elevated CRP, NLR, and age were associated with increased risk, while Beta blockers, ACEI/ARB/ARNI, and lower BNP values were associated with reduced risk.",,,,,
med:pmid:40261428,med:pmid:40261428:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"Prior to the index admission, chronic HF cases were receiving diuretics, beta blockers, ACEi/ARBs, ARNI, MRAs, and SGLT2i at 79.8%, 74.4%, 43.3%, 10.8%, 40.7%, and 14%, respectively.",,,,,
med:pmid:40265590,med:pmid:40265590:sec:conclusion:sent:12,enalapril,sacubitril_valsartan,conclusion,"In PARADIGM-HF, sacubitril/valsartan, compared with enalapril, reduced the risk of HF hospitalizations, death from cardiovascular causes, and death from any cause similarly in women and men with HF with reduced ejection fraction.",,,,,
med:pmid:40265590,med:pmid:40265590:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"Compared with enalapril, sacubitril/valsartan reduced the risk of the primary end point to a similar extent in both sexes: hazard ratios, 0.76 (95% CI, 0.62-0.94) in women and 0.80 (95% CI, 0.73-0.89) in men (<i>P</i>-interaction=0.62).",,,,,
med:pmid:40268473,med:pmid:40268473:sec:results:sent:2,enalapril,sacubitril_valsartan,results,Sixty-four HF outpatients with LVEF <50% were randomized to ARNI (switching from an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [ACEi/ARB] to ARNI) or control (continuing with ACEi/ARB).,,,,,
med:pmid:40302030,med:pmid:40302030:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"HF drug prescription rates were as follows: ACEI 46.3%, ARB 31.8%, ARNI 12.1%, BB 80.9%, MRA 35.6%, SGLT2i 7.3%.",,,,,
med:pmid:40353367,med:pmid:40353367:sec:discussion:sent:10,enalapril,sacubitril_valsartan,discussion,"Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children.",,,,,
med:pmid:40353367,med:pmid:40353367:sec:discussion:sent:8,enalapril,sacubitril_valsartan,discussion,"of 361 paediatric patients (sacubitril/valsartan, n = 179; enalapril, n = 182) demonstrated overall higher baseline NT-proBNP levels in younger AGs.",,,,,
med:pmid:40353367,med:pmid:40353367:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"Associations between baseline NT-proBNP levels, changes post-baseline and the risk of HF clinical events in paediatric patients on sacubitril/valsartan or enalapril were assessed.",,,,,
med:pmid:40397431,med:pmid:40397431:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"Among 7085 sacubitril/valsartan users and 359 153 ACEI/ARB users, 6930 sacubitril/valsartan users [mean (SD) age, 61.7 (14.6) years; 70.9% male] were matched on propensity score to 27 720 ACEI/ARB users [mean (SD) age, 61.7 (15.8) years; 71.1% male].",,,,,
med:pmid:40397431,med:pmid:40397431:sec:results:sent:9,enalapril,sacubitril_valsartan,results,Sacubitril/valsartan showed a 16% lower risk of dementia compared with ACEI/ARB (HR 0.84; 95% CI 0.72-0.98).,,,,,
med:pmid:40470816,med:pmid:40470816:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"At baseline, beta-blockers, angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNi), mineralocorticoid receptor antagonist (MRA) and loop diuretic use was 84% versus 86%, 89% versus 88%, 57% versus 46% and 62% versus 59% in patients receiving versus not receiving CRT, respectively.",,,,,
med:pmid:40470816,med:pmid:40470816:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"A significant association between CRT and the likelihood of ACEi/ARB/ARNi and MRA optimization (OR 1.22, 95% CI 1.04-1.44, and OR 1.25, 95% CI 1.05-1.50, respectively) was observed in the per-protocol analysis.",,,,,
med:pmid:40486108,med:pmid:40486108:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Substituting ACEIs/ARBs with ARNIs significantly improved the NYHA functional class (log odds ratio [log OR] 0.67, 95% CI 0.15-1.19; <i>p</i> = 0.01).",,,,,
med:pmid:40575771,med:pmid:40575771:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"Currently, GDMT recommendations mainly include five types of drugs: diuretics, angiotensin receptor-neprilysin inhibitors (ARNIs), renin-angiotensin system inhibitors (ACEIs/ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i).",,,,,
med:pmid:40660106,med:pmid:40660106:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"Notably, 82% of patients were initiated on three or four drug classes concurrently at the start of treatment, most commonly including RAS inhibitors, MRAs, and beta-blockers, with a preference for ARNI over ACE inhibitors or ARBs.",,,,,
med:pmid:40679772,med:pmid:40679772:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"Among all patients in our study, 61.6% received either an angiotensin-converting enzyme inhibitor, angiotensin-II receptor blocker, or angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI); 57.0% were prescribed β-blockers; and 32.6% used a sodium-glucose cotransporter 2 inhibitor.",,,,,
med:pmid:40718065,med:pmid:40718065:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs).",,,,,
med:pmid:40718065,med:pmid:40718065:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Among patients with HFrEF, those receiving triple therapy (ACEI/ARB/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014).",,,,,
med:pmid:40727001,med:pmid:40727001:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"LASSO regression showed that the key predictors included age, BNP, New York Heart Association (NYHA) class, LVEF, PLR, MLR, AF history, and ACEI/ARB/ARNI usage.",,,,,
med:pmid:40788620,med:pmid:40788620:sec:results:sent:3,enalapril,sacubitril_valsartan,results,CARE-HK in HF was a multinational prospective registry of outpatients with HF (regardless of left ventricular ejection fraction [LVEF]) treated with an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and either receiving or potential candidate for a mineralocorticoid receptor antagonist (MRA).,,,,,
med:pmid:40788620,med:pmid:40788620:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"included frequency of hyperkalaemic events (defined by clinician report with associated potassium value), achievement of renin-angiotensin system inhibitor (RASi) optimization (defined as ≥50% target doses for ACEI/ARB/ARNI and MRA), medication changes following hyperkalaemic episodes, and clinical events.",,,,,
med:pmid:40791946,med:pmid:40791946:sec:results:sent:14,enalapril,sacubitril_valsartan,results,"RAAS inhibitors including ACE inhibitors (18.1%), ARBs (25.2%), and ARNI (10.8%), were also frequently used.",,,,,
med:pmid:40873622,med:pmid:40873622:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,ARNI significantly reduced MEE compared with ACEI/ARB.,comparative,comparative_efficacy,0.6,0,text_too_short
med:pmid:40910162,med:pmid:40910162:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"A combination of angiotensin receptor blocker/neprilysin inhibitors (ARNi)+β-blockers (BB)+sodium-glucose cotransporter 2 inhibitors (SGLT2i; MD, +5.3 [+0.4, +10.3]) was the most effective at improving quality of life followed by ARNi+BB+mineralocorticoid receptor antagonists (MRA)+SGLT2i (MD, +7.1 [-1.0 to +15.2]), ACE inhibitor+BB+MRA+SGLT2i (MD, +5.3 [-2.6, to +13.3]), and ACE inhibitor+BB+MRA+ivabradine (MD, +5.2 [-3.1 to +13.6]), which were not statistically significant.",,,,,
med:pmid:40916703,med:pmid:40916703:sec:results:sent:4,enalapril,sacubitril_valsartan,results,Participants were randomized 1:1 to sacubitril/valsartan (97/103 mg bid) or enalapril (10 mg bid).,,,,,
med:pmid:40993994,med:pmid:40993994:sec:results:sent:4,enalapril,sacubitril_valsartan,results,"In the total population, from admission to discharge there was a increase in the use of angiotensin receptor-neprilysin inhibitor (ARNI) (17.1% to 34.3%), beta-blockers (69.4% to 92.4%), mineralocorticoid receptor antagonists (MRA) (44.0% to 82.1%) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) (30.8% to 79.9%), with a reduction in angiotensin-converting enzyme inhibitor (ACEI) use (all p < 0.05).",,,,,
med:pmid:40993994,med:pmid:40993994:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"Similar trends were observed across HF phenotypes, including HFrEF (increased use of ARNI, 26.3% to 55.1%, beta-blockers, 69.8% to 95.3%, MRA 49.5% to 89.0%, and SGLT2I 36.2% to 79.8%, and lower ACEI use, all p < 0.05).",,,,,
med:pmid:41016569,med:pmid:41016569:sec:conclusion:sent:7,enalapril,sacubitril_valsartan,conclusion,"Compared with ACEI/ARB, ARNI demonstrated enhanced preservation of cardiac function, attenuation of adverse ventricular remodeling, and maintenance of ventricular geometry following myocardial infarction.",,,,,
med:pmid:41049960,med:pmid:41049960:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"Among 236 eligible patients, only 16.5%, 10.2%, 31.4%, and 42.8% were receiving target doses of beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i, respectively.",,,,,
med:pmid:41070303,med:pmid:41070303:sec:conclusion:sent:10,enalapril,sacubitril_valsartan,conclusion,LBBP combined with sacubitril/valsartan is more effective in treating elderly CHD with CHF than LBBP combined with enalapril.,,,,,
med:pmid:41070303,med:pmid:41070303:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"Of them, 53 patients comprised the LBBP & sacubitril/valsartan group and 58 patients comprised the LBBP & enalapril group.",,,,,
med:pmid:41079061,med:pmid:41079061:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"The most expensive medication regime for HF in Venezuela was ARNI-based GDMT with a median monthly cost of 393.81USD, followed by ARB-based GDMT and ACEi-based GDMT costing $100.88USD and $82.23USD respectively.",,,,,
med:pmid:41084891,med:pmid:41084891:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"In this subgroup, the use of angiotensin receptor‑neprilysin inhibitor (ARNI) / angiotensin‑converting enzyme inhibitor (ACEI) / angiotensin receptor blocker (ARB) increased from 81.5% of the patients at admission to 88.9% at discharge, of β‑blocker from 85% to 94.4%, of mineralocorticoid receptor antagonist (MRA) from 69.7% to 86.1%, and of sodium‑glucose cotransporter 2 inhibitor (SGLT2i) from 59.2% to 83.6%.",,,,,
med:pmid:41084891,med:pmid:41084891:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"ARNI/ACEI/ARB therapy was optimized in 36.2% of the participants, while the rates of optimization were 24.7%, 27.2%, and 24.4% for β‑blockers, MRA, and SGLT2i, respectively.",,,,,
med:pmid:41084891,med:pmid:41084891:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"However, only 64 patients (22.3%) attained the 4‑pillar GDMT of SGLT2i, ARNI/ACEI/ARB, β‑blockers, and MRA at doses equal to or above 50% of the target dose.",,,,,
med:pmid:41126807,med:pmid:41126807:sec:conclusion:sent:15,enalapril,sacubitril_valsartan,conclusion,"Among patients with HFrEF seen at the outpatient, there is good physician adherence to betablockers, ACEI/ARNI/ARBs, and diuretics.",,,,,
med:pmid:41126807,med:pmid:41126807:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"Over three months of follow-up, improvement in the quality of care was demonstrated with ACEI/ARNI/ARBs (81.8% to 90.9%), MRA (68.7 to 81.2%), and SGLT2i (58% to 67.7%).",,,,,
med:pmid:41126807,med:pmid:41126807:sec:results:sent:13,enalapril,sacubitril_valsartan,results,"In the 3<sup>rd</sup> month post-discharge, titration to optimal doses was achieved in only 26.4%, 15%, and 6.25% for those on beta-blockers, ACEI/ARNI/ARB, and MRA, respectively.",,,,,
med:pmid:41126807,med:pmid:41126807:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Overall, adherence to prescription of beta-blockers (94.8%), ACEI/ARNI/ARBs (88.5%), and diuretics (100%) were high.",,,,,
med:pmid:41136931,med:pmid:41136931:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Target dose attainment varied by drug class: 78% for beta-blockers, 63% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine.",,,,,
med:pmid:41296625,med:pmid:41296625:sec:conclusion:sent:11,enalapril,sacubitril_valsartan,conclusion,Beta-blockers were discontinued less often than were ACEi/ARB/ARNI.,,,,,
med:pmid:41296625,med:pmid:41296625:sec:results:sent:5,enalapril,sacubitril_valsartan,results,"At diagnosis, 60% of patients were on beta-blockers, 58% on ACEi/ARB/ARNI, and 35% on MRA.",,,,,
med:pmid:41335448,med:pmid:41335448:sec:results:sent:10,enalapril,sacubitril_valsartan,results,A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF.,,,,,
med:pmid:41335448,med:pmid:41335448:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (-54.3% to -0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (-31.9% to 37.5%) decrease (7.2% wins).",,,,,
med:pmid:41335448,med:pmid:41335448:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).",,,,,
med:pmid:41335448,med:pmid:41335448:sec:results:sent:9,enalapril,sacubitril_valsartan,results,"Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group.",,,,,
med:pmid:41408894,med:pmid:41408894:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Among HFmrEF, 88% were on beta-blockers, 34% on ACEi/ARB, 49% on ARNI, 63% on MRA, and 59% on SGLT2i.",,,,,
med:pmid:41408894,med:pmid:41408894:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"In the HFpEF group, 76% were on beta-blockers, 49% on ACEi/ARB, 18% on ARNI, 49% on MRA and 40% on SGLT2i.",,,,,
med:pmid:41408894,med:pmid:41408894:sec:results:sent:6,enalapril,sacubitril_valsartan,results,"Among HFrEF, prescription frequencies were: 90% for beta-blockers; 19% for angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB); 61% for angiotensin receptor-neprilysin inhibitors (ARNI); 72% for mineralocorticoid receptor antagonists (MRA); and 69% for sodium-glucose co-transporter 2 inhibitors (SGLT2i).",,,,,
ppr:doi:10.1101/2023.10.31.23297731,ppr:doi:10.1101/2023.10.31.23297731:sec:conclusion:sent:16,enalapril,sacubitril_valsartan,conclusion,"Physicians’ level of adherence to prescription and up-titration of GDMT was satisfactory for ACEI/ARNI/ARBs and B-blockers, however, it was poor for SGLT2is and MRAs.",,,,,
ppr:doi:10.1101/2023.10.31.23297731,ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:11,enalapril,sacubitril_valsartan,results,"GAI at discharge were 66.2%, 71.7%, and 42.6% for ACEI/ARNI/ARBs, B-blockers, and MRAs, respectively.",,,,,
ppr:doi:10.1101/2023.10.31.23297731,ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:14,enalapril,sacubitril_valsartan,results,"The proportions for good QUALIFY scores for ACEI/ARNI/ARBs, B- blockers, and MRAs were 35.8%, 38.5%, and 9.5%, respectively.",,,,,
ppr:doi:10.1101/2023.10.31.23297731,ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:15,enalapril,sacubitril_valsartan,results,"Uptitration to ≥ 50% of target dose was done in 51.9%, 48.7%, and 7.9% of patients for ACEI/ARNI/ARBs, B- blockers, and MRAs, respectively.",,,,,
ppr:doi:10.1101/2025.01.10.25320367,ppr:doi:10.1101/2025.01.10.25320367:sec:results:sent:8,enalapril,sacubitril_valsartan,results,"The groups were well matched for age: 52.9±11.3 (IVB) vs. 53.5±11.8, gender: 57% male, HFrEF diagnosis: 66.4%, co-morbidities: hypertension 81.3% and coronary artery disease event 38.3%, and goal-directed medical therapy: ß-adrenergic blockers 89.7%, ACEi/ARB/sacubitril/valsartan 79.4%, mineral corticoid antagonists 39.3%.",,,,,
ppr:doi:10.1101/2025.03.12.25323680,ppr:doi:10.1101/2025.03.12.25323680:sec:results:sent:7,enalapril,sacubitril_valsartan,results,"The combinations which resulted in the greatest improvement of quality of life were ARNi + BB + MRA + SGLT2i [MD 7.11 (95% CI -0.99-15.22)], which did not have a statistically significant effect, followed by ARNi + BB + SGLT2i [MD 5.33 (95% CI 0.40-10.25)], ACEi + BB + MRA+ SGLT2i [MD 5.32 (95% CI -2.63-13.26)], ACEi + BB + MRA + ivabradine [MD 5.24 (95% CI -3.07-13.55)].",,,,,
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:conclusion:sent:13,enalapril,sacubitril_valsartan,conclusion,Regardless of significant improvement of baseline LVEF observed in patients receiving both ACEI/ARB and ARNI in 6 week follow-up the value of absolute and relative LVEF increase were higher in subjects treated with ACEI/ARB.,,,,,
ppr:doi:10.21203/rs.3.rs-7118793/v1,ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:results:sent:10,enalapril,sacubitril_valsartan,results,"Target dose attainment varied by drug class: 46% for beta-blockers, 41% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine.",,,,,
